9 January 2021 - pERC has conditionally recommended the reimbursement of entrectinib for the first-line treatment of patients with ROS1 positive locally advanced or metastatic non-small cell lung cancer if certain conditions are met.
One of the conditions is that the cost effectiveness needs to be improved to an acceptable level.